MCAP MedCap AB (publ)
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; and Assistive Tech including digital and physical solutions in cognition, communication, environmental control, alarms, mobility, accessibility, and orthotics. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe. It typically invests between SEK25 million ($2.75 million) and SEK150 million ($16.51 million) with enterprise value SEK50 million ($5.90 million) and SEK250 million ($23.06 million) and sales value between 5 million ($5.43 million) and 25 million ($27.18 million) and EBITDA between SEK1 million ($0.11 million) and SEK50 million ($5.50 million). The firm seeks to takes both minority and majority stakes. It uses its capital and loans and makes balance sheet investments. The company was founded in 2001 and is based in Stockholm, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About MedCap (STO: MCAP)
›
MedCap (STO: MCAP) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 663 employees.
The shares were at 550.50 SEK on 19 November 2026, down 0.6% over 52 weeks. Its 52-week range is 440.00 SEK to 604.50 SEK: the price is 8.9% below the high and 25.1% above the low.
At a market capitalisation of 8.24B SEK, it trades at 30.1 times trailing earnings and 108.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 17% for MCAP.
MedCap reports return on equity of 15.1%, an operating margin of 16.3% and revenue up 20.4% year over year.
Its debt exceeds its cash by 164.90M SEK, a debt-to-equity ratio of 0.33. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 647.50 SEK is 17.6% above the current price. The next earnings report is expected on 5 February 2027.